Methods of using zonisamide as an adjunctive therapy for partial seizures
are disclosed. In particular, the methods enhance the safety of patients
taking pharmaceutical formulations of zonisamide by providing information
that increases the awareness of rhabdomyolysis and/or elevated CPK as
possible side effects; wherein the patients and/or prescribing physicians
and other medical care providers are advised to monitor for such
conditions and employ methods that will improve the therapeutic outcome
in the few patients who experience rhabdomyolysis and/or elevated CPK
associated with zonisamide therapy.
